Reading the evidence
Ask what the evidence actually supports.
Ask for evidence about the named product, the proposed use, and the result that matters to you. Then ask what the evidence leaves unanswered.
To begin
Product approval and personal care differ
Semaglutide and tirzepatide are medicine ingredients used for blood sugar or weight. As of September 2026, Ozempic (semaglutide) and Mounjaro (tirzepatide) are approved to control blood sugar in people with type 2 diabetes. Wegovy (semaglutide) and Zepbound (tirzepatide) are approved for weight loss alongside changes to eating and physical activity.
These are some approved uses, not the whole list. Ask which product’s official prescribing information supports the proposed use for you.
Look a little closer
A medicine made for one patient needs its own explanation
A compounded medicine is prepared or altered for an individual patient, rather than supplied as a finished product by a drug company.
The US drug agency is the Food and Drug Administration, known here as FDA. For compounded medicines, FDA has not assessed safety, quality, or whether they work before sale, as of September 2026.
Claiming that a compounded drug gives the same proven results as an approved drug is false or misleading, according to FDA as of September 2026.
Ask whether the evidence is about this exact medicine or a different finished product.
Look a little closer
Taking back a request does not make a medicine approved
The peptide named BPC-157 has been proposed for use as an ingredient in medicines prepared by pharmacies. FDA’s list, current as of April 22, 2026, includes it among ingredients whose supporters took back their requests. FDA still lists safety concerns beside those ingredients.
The requests asked FDA to put ingredients on a list for pharmacy compounding. Taking a request back does not give permission to use the ingredient or make it FDA-approved, as of September 2026.
Look a little closer
Ask what is still unknown
Was the evidence about this product and this purpose?
Which result was measured?
What questions did the study leave open?
What would change the care plan if it did not help?
Chapter recap
Keep this in mind.
Keep the product, proposed use, and evidence in the same conversation. Ask for the source rather than a broad claim of proof.